Genfit SA
GNFT4.850USD
0.000
Close 12/26, 16:00（ET）Quotes delayed by 15 min
242.51MMarket Cap
--P/E TTM
More Details of Genfit SA Company
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Genfit SA Info
Ticker SymbolGNFT
Company nameGenfit SA
IPO dateDec 19, 2006
CEOPrigent (Pascal)
Number of employees180
Security typeDepository Receipt
Fiscal year-endDec 19
AddressParc Eurasante 885 avenue Eugene Avinee
CityLOOS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code59120
Phone33320164000
Websitehttps://www.genfit.fr/
Ticker SymbolGNFT
IPO dateDec 19, 2006
CEOPrigent (Pascal)
Company Executives of Genfit SA
Name
Name/Position
Position
Shareholding
Change
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Mr. John Brozek
Mr. John Brozek
Executive Vice President - Data and Information Technology
Executive Vice President - Data and Information Technology
--
--
Mr. Jean-Christophe Marcoux
Mr. Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AllianceBernstein L.P.
0.04%
Morgan Stanley & Co. International Plc
0.04%
Summit Financial, LLC
0.04%
UBS Financial Services, Inc.
0.01%
Other
99.87%
Shareholders
Shareholders
Proportion
AllianceBernstein L.P.
0.04%
Morgan Stanley & Co. International Plc
0.04%
Summit Financial, LLC
0.04%
UBS Financial Services, Inc.
0.01%
Other
99.87%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
0.05%
Investment Advisor
0.05%
Research Firm
0.04%
Other
99.86%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
20
80.73K
0.16%
-686.95K
2025Q2
22
234.11K
0.47%
-547.30K
2025Q1
25
259.00K
0.52%
-1.29M
2024Q4
26
260.49K
0.52%
-1.21M
2024Q3
28
127.35K
0.26%
-1.36M
2024Q2
31
97.15K
0.20%
-1.36M
2024Q1
31
97.93K
0.20%
-1.42M
2023Q4
31
648.17K
1.30%
-1.34M
2023Q3
32
1.16M
2.33%
-1.43M
2023Q2
30
1.77M
3.54%
-496.41K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AllianceBernstein L.P.
22.36K
0.04%
+13.38K
+148.94%
Jun 30, 2024
Morgan Stanley & Co. International Plc
27.42K
0.05%
+1.90K
+7.45%
Jun 30, 2025
UBS Financial Services, Inc.
4.08K
0.01%
+963.00
+30.89%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.21K
0.01%
--
--
Aug 31, 2025
Osaic Holdings, Inc.
225.00
0%
+225.00
--
Jun 30, 2025
Principal Securities Inc
24.00
0%
+24.00
--
Jun 30, 2025
Qube Research & Technologies Ltd
--
0%
-98.00
-100.00%
Sep 30, 2024
BofA Global Research (US)
1.00
0%
-16.00
-94.12%
Jun 30, 2025
Millennium Management LLC
--
0%
-131.48K
-100.00%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Genfit SA?
The top five shareholders of Genfit SA are:
AllianceBernstein L.P. holds 22.36K shares, accounting for 0.04% of the total shares.
Morgan Stanley & Co. International Plc holds 27.42K shares, accounting for 0.05% of the total shares.
UBS Financial Services, Inc. holds 4.08K shares, accounting for 0.01% of the total shares.
Geode Capital Management, L.L.C. holds 3.21K shares, accounting for 0.01% of the total shares.
Osaic Holdings, Inc. holds 225.00 shares, accounting for 0.00% of the total shares.
AllianceBernstein L.P. holds 22.36K shares, accounting for 0.04% of the total shares.
Morgan Stanley & Co. International Plc holds 27.42K shares, accounting for 0.05% of the total shares.
UBS Financial Services, Inc. holds 4.08K shares, accounting for 0.01% of the total shares.
Geode Capital Management, L.L.C. holds 3.21K shares, accounting for 0.01% of the total shares.
Osaic Holdings, Inc. holds 225.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Genfit SA?
The top three shareholder types of Genfit SA are:
AllianceBernstein L.P.
Morgan Stanley & Co. International Plc
Summit Financial, LLC
AllianceBernstein L.P.
Morgan Stanley & Co. International Plc
Summit Financial, LLC
How many institutions hold shares of Genfit SA (GNFT)?
As of 2025Q3, 20 institutions hold shares of Genfit SA, with a combined market value of approximately 80.73K, accounting for 0.16% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.31%.
What is the biggest source of revenue for Genfit SA?
In --, the -- business generated the highest revenue for Genfit SA, amounting to -- and accounting for --% of total revenue.
